CTLA4 and breast carcinoma: As we have previously reported40, dual anti-PD-1/anti-CTLA-4 therapy is ineffective in controlling tumor growth in KEP mice bearing spontaneous mammary tumors (Figure 1B,C), consistent with poor response to ICB as monotherapy in breast cancer patients1,2.